Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$1.57 USD
+0.03 (1.77%)
Updated Aug 30, 2024 03:59 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
CRLBF 1.57 +0.03(1.77%)
Will CRLBF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRLBF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRLBF
AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates
Universal Health Services (UHS) Q2 Earnings and Revenues Surpass Estimates
CRLBF: What are Zacks experts saying now?
Zacks Private Portfolio Services
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
Will Cresco Labs Inc. (CRLBF) Report Negative Earnings Next Week? What You Should Know
AdaptHealth Corp. (AHCO) Lags Q1 Earnings Estimates
Other News for CRLBF
American views on marijuana effects worsening: Gallup
Cresco Labs Remains Strong Amidst Rescheduling Uncertainties (Hold)
Largest Cannabis Stocks Are Down +10% In Last Two Days: Here's Why
Marijuana rescheduling unlikely to lead to cannabis banking reform
Cannabis Stocks Plummet By Up To 16% On DEA Rescheduling Delay: Could This Be The Buying Opportunity Of 2024?